Martin Hausberg

Prof. Dr. Martin Hausberg

Department of Medicine I - Nephrology, Rheumatology, Pneumology and General Inernal Medicine, Department of Medicine I, Karlsruhe General Hospital, Karlsruhe, Baden-Württemberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2019 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
MHMartin Hausberg
Martin Hausberg
HFHelmut Felten
Helmut Felten
SPStefan Pfeffer
Stefan Pfeffer
The unexpected occurrence of thrombotic microangiopathy (TMA), characterised by microangiopathic haemolytic anaemia and thrombocytopenia, in a patient with cancer requires urgent diagnosis and appropriate management. TMA in patients with metastatic cancer can be a manifestation of the malignancy itself or a therapeutic complication. Distinguishing the cause of TMA is complicated but clinically important to initiate appropriate treatment of metastatic cancer and avoid potential drug toxicity. Eculizumab, which inhibits alternative complement pathway activation, has been shown to be effective in chemotherapy-induced TMA. We report the case of a 69-year-old woman with breast cancer who experienced a mitomycin-C-induced TMA manifestation. TMA did not respond to conservative therapy, plasmapheresis or rituximab and rapidly lead to dialysis dependency. Despite disease progression and metastases, eculizumab treatment was associated with recovered renal function and enabled the patient to avoid dialysis, improving her quality of life.

1 December 2008 in Journal Of Hypertension
Verified
Journal Article
Closed access
MHMartin Hausberg
Martin Hausberg
UHUta Hillebrand
Uta Hillebrand
KKKlaus Kisters
Klaus Kisters

1 April 2012 in Trace Elements and Electrolytes
Verified
Journal Article
Closed access
KKKlaus Kisters
Klaus Kisters
FWFranz Wessels
Franz Wessels
MNMichael Q. Nguyen
Michael Q. Nguyen
AMAnna Mitchell
Anna Mitchell
BGBernhard Gremmler
Bernhard Gremmler
FTFaruk Tokmak
Faruk Tokmak

23 April 2021 in Dialyse aktuell
Verified
Journal Article
Closed access
PDF file
MHMartin Hausberg
Martin Hausberg
Die diabetische Nephropathie, eine Manifestation der diabetischen Mikroangiopathie, ist weiterhin die häufigste Ursache der terminalen dialysepflichtigen Niereninsuffizienz in den Industrienationen. Dies zeigen u. a. aktuelle Daten des Registers der „European Renal Association – European Dialysis and Transplant Association“ (ERA-EDTA) 1. Die Pathophysiologie der diabetischen Nephropathie ist komplex. Wesentliche Progressionsfaktoren sind Hyperfiltration und Inflammation neben mangelhafter Kontrolle des Glukosestoffwechsels (Abb. 2).

2 June 2016 in DMW - Deutsche Medizinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
BSBernd Sanner
Bernd Sanner
MHMartin Hausberg
Martin Hausberg
Hypertonie-Patienten ohne Diabetes mit hohem kardiovaskulären Risiko sollten auf einen Ziel-Blutdruck von kleiner als 130 mmHg eingestellt werden. Ältere Hypertoniker, die körperlich fit sind, haben die gleichen Ziel-Blutdruckwerte wie jüngere Hypertoniker, nicht aber gebrechliche Hypertoniker mit einem Alter von über 80 Jahren, die bei straffer Blutdruckeinstellung eine erhöhte Morbidität und Mortalität aufweisen. Bei schlecht einstellbarer oder therapierefraktärer Hypertonie zeigt Spironolacton als vierte antihypertensiv wirksame Substanz zusätzlich zum ACE-Hemmer/Angiotensin-Rezeptorblocker, Kalziumantagonisten und Thiaziddiuretikum den stärksten Effekt. In patients with hypertension without diabetes and with an increased risk of cardiovascular complications a blood pressure of below 130 mmHg should be targeted. Hypertensive patients with an age above 80 years should be treated in the same way as younger hypertensive patients if they are otherwise healthy and functionally independent. On the other hand frail elderly patients could have an increased morbidity and mortality with intensive blood pressure control. In patients with resistant hypertension spironolactone was the most effective drug when given in addition to their baseline drugs (ACE-inhibitor/angiotensin receptor antagonist, calcium channel blocker and thiazide diuretic).

26 April 2009 in Der Nephrologe
Verified
Journal Article
Closed access
PDF file
MHMartin Hausberg
Martin Hausberg